Erasca and Eli Lilly announced that they have entered into a clinical trial collaboration and supply agreement for Erbitux® (cetuximab). This agreement will support Erasca’s ongoing Ph I trials evaluating ERAS-601, its SHP2 inhibitor, with cetuximab for the treatment of triple wildtype metastatic colorectal cancer and HPV-negative advanced head and neck squamous cell carcinoma. Lilly will supply cetuximab to Erasca at no cost.
High Court Ends 14-Year Clopidogrel Dispute: Commonwealth’s Claim for Damages Dismissed in 3:2 Split Decision
Commonwealth of Australia v Sanofi [2024] HCA 47 Date of decision: 11 December 2024 Body: High Court of Australia Adjudicator: Justices...